A phase II study of loratidine (L) to prevent pegfilgrastim-induced pain (PIP).
Jeffrey J. Kirshner(American Society of Clinical Oncology), G Morrow, Carol Reichel, Stephen T. Tiffany(University at Buffalo, State University of New York), Charles E. Heckler(University of Rochester Medicine), Christin M. Giordano McAuliffe
Cited by 5
Related Papers
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
|JAMA Oncology|2017|913
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
|Journal of Clinical Oncology|2001|819
Prevalence, Demographics, and Psychological Associations of Sleep Disruption in Patients With Cancer: University of Rochester Cancer Center–Community Clinical Oncology Program
|Journal of Clinical Oncology|2009|564
Applied Discriminant Analysis
|Technometrics|1995|409